## Fragile X Syndrome, Carrier

Order Name: FRAGILE X Test Number: 0117075 Revision Date: 03/11/2024

| TEST NAME                     |   |   | METHODOLOGY                   | LOINC CODE            |  |
|-------------------------------|---|---|-------------------------------|-----------------------|--|
| Fragile X Syndrome, Carrier   |   |   | PCR/Capillary Electrophoresis | 53039-4               |  |
| SPECIMEN REQUIREN             | MENTS   |   |                               |                       |  |
|                               |   |   |                               |                       |  |
| Specimen                      | Specimen Volume (min)   | Specimen Type   | Specimen Container            | Transport Environment |  |
| Preferred                     | 8.5 mL (3 mL)   | Whole Blood   | EDTA (Lavender Top)           | Room Temperature      |  |
| Alternate 1                   | 1   | See Instructions  | See Instructions              | Room Temperature      |  |
| Instructions                  | Collection: Standard phlebotomy<br>chew gum 30 minutes prior to coll<br>Specimen Storage: Room tempe  | imen Type: 8.5 mL whole blood from Lavender-top (EDTA) tube OR PurFlock buccal swab kit or Oragene Dx saliva kit<br>ection: Standard phlebotomy. Follow PurFlock buccal swab kit or Oragene Dx 500 saliva kit collection instructions. Do not eat, drink, smoke or<br>gum 30 minutes prior to collection.<br>imen Storage: Room temperature<br>litty: Whole blood: 14 days at room temperature or 30 days at 4'C  |                               |                       |  |
|                               |   |   |                               |                       |  |
| GENERAL INFORMATION           |   |   |                               |                       |  |
| Expected TAT                  | 6-14 Days   |   |                               |                       |  |
| Clinical Use                  | ?Limitations: Technologi<br>including rearrangement<br>between variants, or rep<br>available. False positive<br>pseudogene interference<br>erroneous representation | This test is used for carrier screening for fragile X syndrome (FMR1).<br>?Limitations: Technologies used do not detect germline mosaicism and do not rule out the presence of large chromosomal aberrations including rearrangements and gene fusions, or variants in regions or genes not included in this test, or possible inter/intragenic interactions between variants, or repeat expansions. Variant classification and/or interpretation may change with time if more information becomes available. False positive or false negative results may occur for reasons that include: rare genetic variants, sex chromosome abnormalities, pseudogene interference, blood transfusions, bone marrow transplantation, somatic or tissue-specific mosaicism, mislabeled samples or erroneous representation of family relationships. This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration. |                               |                       |  |
| Performing Labcorp Te<br>Code | <b>st</b> 481684  |   |                               |                       |  |

Polymerase chain reaction (PCR) followed by capillary electrophoresis, with reflex to AGG interruption analysis and methylation PCR analysis for positive samples CPT Code(s) 81243

Lab Section

Notes

Reference Lab

Service provided by Labcorp Oklahoma, Inc. All Rights Reserved. © 2003 - 2025